Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.69 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BAG3 | O95817 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614974 | 0.94 | SLC2A1 (0.77) | SLC2A1COMTALDH1A1KMT2ABAG3 | |
| SCHEMBL1613493 | 0.88 | SLC2A1 (0.89) | SLC2A1KDM4EALDH1A1THRBHPGD | |
| SCHEMBL12737009 | 0.86 | SLC2A1 (0.61) | SLC2A1COMTALDH1A1BAG3PPARG | |
| SCHEMBL1615131 | 0.86 | SLC2A1 (0.61) | SLC2A1COMTBAG3PPARGAKR1B1 | |
| SCHEMBL1614379 | 0.82 | SLC2A1 (1.00) | SLC2A1COMTALDH1A1KMT2ABAG3 | |
| SCHEMBL12712445 | 0.79 | SLC2A1 (0.61) | SLC2A1COMTKDM4EALDH1A1THRB | |
| SCHEMBL1614903 | 0.78 | SLC2A1 (0.51) | SLC2A1COMTKDM4EALDH1A1THRB | |
| SCHEMBL1614304 | 0.76 | SLC2A1 (0.52) | SLC2A1COMTKDM4EALDH1A1KMT2A | |
| SCHEMBL1614533 | 0.76 | NLRP3 (0.55) | SLC2A1KMT2APPARG | |
| SCHEMBL1614850 | 0.75 | PRKAG1 (0.54) | SLC2A1COMTBAG3PPARGAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488027-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | The Ohio State University Research Foundation (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011044548-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | claimed |
| US-8383656-B2 | Thiazolidinedione energy restriction-mimetic agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086895-A1 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS | PCK2, AK2, SIRT6 | SLC2A1 76/4885COMT 4225/4885KDM4E 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.